Clinical trials: Type 2 Diabetes (T2D)
Type 2 Diabetes
Observational Study of Effectiveness and Tolerability of Gliclazide MR 60mg in Diabetic Patients Fasting During RAMADAN
The purpose of this observational study is to assess effectiveness and tolerability of gliclazide MR 60mg during RAMADAN in a real world setting in 9 countries from Asia Pacific and Middle East/North Africa
- Trial name
- DIA-RAMADAN (NCT04132934)
- Where
- France
- Volunteers
- 1,200 people
- Sponsor
- Servier Affaires Médicales
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Feasibility Study of Blood Glucose Monitoring With the Non-invasive Medical Device D-Base
This study aims to evaluate the feasibility of monitoring the blood glucose values by measuring the glucose in the interstitial fluid of the skin on the wrist of subjects with diabetes mellitus type 1 and 2.
- Trial name
- NCT05169034
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Diamontech AG
Diabetes Mellitus, Type 2
CGM Use in Adults With Type 2 Diabetes on Basal Insulin
A prospective multi-centre, open-label, two arm, parallel design, superiority, pragmatic, randomised controlled trial, over an 8-month period.
- Trial name
- NCT05944432
- Testing
- FreeStyle Libre 3 Continuous Glucose Monitoring System., Self monitoring of blood glucose
- Where
- 25 sites in United Kingdom
- Volunteers
- 469 people
- Sponsor
- Abbott Diabetes Care
Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate the Efficacy and Safety of AD-233A, AD-233B, AD-233C and/or AD-233D Combination Therapy
The purpose of this study is to evaluate the efficacy and safety of AD-233A, AD-233B, AD-233C and/or AD-233D combination therapy
- Trial name
- NCT07816198
- Testing
- AD-233A, AD-233B, AD-233C
- Volunteers
- 354 people
- Sponsor
- Addpharma Inc.
Diabetes, Diabetes Mellitus, Type 1
A Two Part Trial Investigating NN1952 in Healthy Subjects and Subjects With Type 1 and Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the safety, tolerance, pharmacokinetics (exposure of drug) and pharmacodynamics (effect) of NN1952 as tablets in healthy volunteers and subjects with type…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT01028404
- Testing
- NN1952, insulin aspart
- Where
- Germany
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Two-Part, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DS-7309 in Healthy Volunteers and Subjects With Type 2 Diabetes Mellitus
This is a randomized, placebo-controlled, 2-part, sequential, single ascending dose study. Part 1 is planned as 6 sequential escalation treatment groups.
- Trial name
- NCT01862939
- Testing
- DS-7309
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes Mellitus
Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes
The purpose of this study is to examine the effect CGM (continuous glucose monitoring) has on subjects with type 2 diabetes. It is anticipated that patients using the device will obtain tighter control of their blood sugars…
- Trial name
- DexlonT2 (NCT01341067)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rocky Mountain Diabetes and Osteoporosis Center
Type 2 Diabetes Mellitus
Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus
Determine the safety and efficacy of MK-0431/ONO-5435 in patients with Type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy
- Trial name
- NCT00363844
- Testing
- Sitagliptin phosphate
- Where
- 8 sites in Japan
- Volunteers
- 209 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Type II Diabetes
Pharmacokinetics and Safety/Tolerability After Oral Administration of CKD-387 and D484 in Healthy Adults
Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability after Oral Administration of CKD-387 10/1000 mg and D484 10/1000mg in Healthy Adults
- Trial name
- NCT03646799
- Testing
- CKD-387, D484
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants
The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA).
- Trial name
- CRISTALSEA (NCT07532863)
- Testing
- No treatment given
- Where
- 6 sites in Indonesia, Malaysia and 2 more
- Volunteers
- 400 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
The reason for this study is to see if the study drug insulin efsitora alfa (LY3209590) is safe and effective in participants with Type 2 diabetes that have already been treated with basal insulin.
- Trial name
- NCT05275400
- Testing
- Insulin Efsitora Alfa, Insulin Degludec
- Where
- 127 sites in United States, Argentina and 8 more
- Volunteers
- 986 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 1 Diabetes
Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes Mellitus
The purpose of this study is to evaluate the effectiveness and safety of the RIGHTEST Continuous Monitoring (CGM) System in adult population with diabetes mellitus.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Type 2 Diabetes
- Trial name
- NCT04838392
- Testing
- RIGHTEST Continuous Glucose Monitoring System
- Where
- 13 sites in United States
- Volunteers
- 150 people
- Sponsor
- Bionime Corporation
Obesity and Type 2 Diabetes
Evaluate the Efficacy and Safety of NT-0796 in Participants With Obesity With or Without Type 2 Diabetes Mellitus
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NT-0796 as an Adjunct to a Reduced Calorie Diet and Increased Physical Activity in Obese Participants With/Without Type 2…
- Trial name
- RESOLVE-1 (NCT07055516)
- Testing
- NT-0796
- Where
- 11 sites in United States
- Volunteers
- 176 people
- Sponsor
- Rezera (formerly NodThera Limited)
Type 2 Diabetes Mellitus
Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled
Primary Objective: -To demonstrate the efficacy of a fixed combination of glimepiride + metformin in terms of HbA1c reduction, during 24-week treatment period in patients with inadequately controlled type 2 diabetes mellitus.
- Trial name
- LEGEND (NCT01699932)
- Testing
- Glimepiride+metformin (Amaryl M®) - HOE4900
- Where
- 13 sites in Lebanon, Russia and 1 more
- Volunteers
- 167 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With GLP-1 Analogue in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with GLP-1 analogue in patients with type 2 Diabetes for 52 weeks.
- Trial name
- NCT02227849
- Testing
- Canagliflozin (TA-7284), GLP-1 analogue
- Where
- 4 sites in Japan
- Volunteers
- 71 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Type 1, Diabetes Type 2 on Insulin
EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation
EkiYou-Study-2 is an interventional multicenter randomised controlled clinical investigation according to EU 2017/745. It is conducted in 154 adults with diabetes and treated by multiple daily insulin injections that will be…
- Conditions
- Diabetes Type 1, Diabetes Type 2 on Insulin, Pancreatogenous Diabetes
- Trial name
- NCT06738849
- Testing
- EkiYou V2
- Where
- 16 sites in France
- Volunteers
- 154 people
- Sponsor
- DiappyMed
Diabetes, Diabetes Mellitus, Type 2
Basal Bolus of Insulin Aspart Including Insulin NPH and Biphasic Insulin Aspart in Type 2 Diabetes
This trial is conducted in Europe and Asia. The aim of this trial is to compare basal bolus treatment with insulin aspart and insulin NPH to biphasic insulin aspart treatment on blood glucose control in type 2 diabetes.
- Trial name
- NCT00600626
- Testing
- biphasic insulin aspart, insulin NPH, insulin aspart
- Where
- 55 sites in Croatia, France and 11 more
- Volunteers
- 394 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Disease
A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease
The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes…
- Trial name
- NCT06717698
- Testing
- NNC0519-0130, Semaglutide
- Where
- 147 sites in United States, Argentina and 12 more
- Volunteers
- 465 people
- Sponsor
- Novo Nordisk A/S
Insulin Resistance - Type A, Insulin Resistance - Type B
A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 )
A multicenter, open-label, single-arm, extension study with regard to the safety and efficacy of empagliflozin in patients with refractory diabetes mellitus with insulin resistance.
- Conditions
- Insulin Resistance - Type A, Insulin Resistance - Type B, Lipoatrophic Diabetes Mellitus, Insulin Resistance Syndrome
- Trial name
- EMPIRE-02 (NCT04221152)
- Testing
- Empagliflozin Tablets
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Kobe University
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study
This is a randomized, double-blind, double-dummy, placebo-controlled, cross over design trial with empagliflozin compared to placebo that is added to open-label ramipril.
- Conditions
- Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity
- Trial name
- NCT02632747
- Testing
- Empagliflozin, ramipril
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.